Found "Public health policy": 1,100 results
Sort by
Last updated

Towards A Sustainable Kidney Replacement Therapy Program: Recommendations For Thailand’s 2022 Dialysis Reform

The National Health Security Office Working Group (NHSO WG) conducted structured, evidence-based deliberations to generate recommendations for the National Health Security Board on the kidney replacement therapy (KRT) policy. These are the proposed recommendations: To consider defining KRT p

Horizon Scanning in the European Union

Horizon Scanning (HS) is the process of identifying new and emerging technologies before uptake into practice to evaluate the potential impact to inform decision-making. In the European Union (EU), the EuroScan International Network was established in 1997 and over time, given its expanded geogr

The Life Saving Drug Program: Australia’s pathway to high-cost drugs

Australia developed the Life-Saving Drugs Program (LSDP) in 1995 to complement the Pharmaceutical Benefits Scheme (PBS), expanding access to high-cost drugs for rare diseases (DRD). This program, funded and administered by the Department of Health and Aged Care, permitted sponsors (often pharmaceuti

Health Financing during COVID-19 responses in Thailand

Thailand spent 440,023 million baht on healthcare in response to the COVID-19 pandemic in 2020–2022, of which 257,892 million baht went toward COVID-19 tests, treatments, and vaccination services. In addition to having higher hospital reserves than in the pre-pandemic period, private hospital

Learning from Cancer Drug Fund (CDF) in England: A special reimbursement pathway for high-cost cancer drugs

The Cancer Drug Fund (CDF) is a dedicated source of funding in England for increasing patient access to high-cost cancer drugs, with a fixed budget of £340 million per year, operating since 2016. The CDF follows the appraisal by the National Institute of Health and Care Excellence (NICE) whic

Experience in Using HTA for Expanding UHC Benefit Package to Cover Rare Diseases and High-Cost Drugs among Seven Middle and High-Income Countries: A targeted literature review

This policy brief provides a summary of a recent review of the definition of rare diseases, high cost and how HTA has been used in the case of rare diseases in seven countries. The countries were purposively selected based on them having established HTA policies and availability of resources in the

Rare diseases – Talk of the Town for Some Time but What’s Next?

Because of their rarity, rare diseases are often treated with what the industry refers to as ‘orphan drugs’. These group of drugs are quite expensive because of the fewer number of people suffering from such sickness and usually provide low profit to manufacturer compared to other common drug for n

eSanjeevani, the National Telemedicine service: Bridging healthcare gaps in India

– eSanjeevani was developed primarily to tackle the challenges of inequitable healthcare access and the shortage of healthcare professionals in India  – The ‘one application’ approach ensured that only one application is used for the national telemedicine service delivery, thus ensuring interoper

Strategies for Sustainable Access: Unpacking Managed Entry Agreements (MEAs) and Innovative Medicine Access

MEAs aim at early access to high-cost innovative medicines at pre-determined terms that can ensure the financial sustainability of healthcare systems. However, their successful adoption hinges on a consideration of various factors to address the unique challenges faced by different nations. The a

Unveiling Thailand’s Path to Open Data for Health Policy

Open data is widely recognized as valuable, especially during the COVID-19 pandemic, highlighting the need for up-to-date information systems, leading all sectors to acknowledge its significance in enhancing efficiency, fairness, and societal development. These open data movements observed during
10 / Page